These efforts have led to new FDA-approved therapies and diagnostic tests widely used for patients with cancer. More recently, his group has developed noninvasive liquid biopsy approaches for early …

These efforts have led to new FDA-approved therapies and diagnostic tests widely used for patients with cancer. More recently, his group has developed noninvasive liquid biopsy approaches for early …

PRESS RELEASES May 12, 2025 DELFI Diagnostics CTO Recognized among 2025 Most Influential Women in Bay Area Business April 25, 2025 DELFI Diagnostics to Present Early Detection and …

Unlocking a Vast Trove of Diagnostic Data Our unique fragmentomics technology isn’t limited to the small number of mutations or alterations detected by other liquid biopsy methods.

DELFI is expanding its team of top talent to help people live longer, healthier, cancer-free lives through widely available, high-performing cancer screening tests.

It was developed and its performance characteristics determined by DELFI Diagnostics. It has not been cleared or approved by the FDA. The laboratory is regulated under the Clinical Laboratory …

Widely Available Screening Effective cancer screening requires a test accessible to everyone who needs one. DELFI’s machine learning tools work with commonly used lab methods and instruments, …

BALTIMORE and PALO ALTO, Calif., July 18, 2022 /PRNewswire/ – DELFI Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early …

A New Way to Help Detect Cancer DELFI’s rigorous clinical trial program produces evidence that our fragmentomics technology and products are suited to make cancer less deadly by helping make …

While cell-free DNA offers tremendous potential for cancer diagnostics, traditional approaches are constrained by the need for tumor-specific mutation data. DELFI overcomes this fundamental …